OTCMKTS:ATMSArtemis Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Artemis Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.22 0.00 (-1.75 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$0.22Now: $0.22▼$0.2250-Day Range$0.04MA: $0.11▼$0.2552-Week Range$0.03Now: $0.22▼$0.45Volume400 shsAverage Volume10,284 shsMarket Capitalization$1.15 millionP/E RatioN/ADividend YieldN/ABeta-4.66 ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Artemis Therapeutics Inc., a biopharmaceutical company, engages in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company's lead product candidate is Artemisone, an orally-administered 10-alpha-amino artemisinin derivative with antiviral and antiparasitic properties. It focuses on advancing Artemisone as an antiparasitic treatment for patients infected with Plasmodium falciparum; and as an antiviral agent to address unmet clinical needs in immunocompromised patients infected with human cytomegalovirus and other viral or infectious diseases. The company has license agreement with Hadasit Medical Research Services and Development Ltd., Hadassah Medical Organization, and Hong Kong University of Science and Technology R and D Corporation Limited for the development of Artemisone. Artemis Therapeutics Inc. was incorporated in 1997 and is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Artemis Therapeutics. Previous Next 2.3 Community Rank Outperform VotesArtemis Therapeutics has received 31 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArtemis Therapeutics has received 36 “underperform” votes. (Add your “underperform” vote.)Community SentimentArtemis Therapeutics has received 53.73% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Artemis Therapeutics and other stocks. Vote “Outperform” if you believe ATMS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATMS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArtemis Therapeutics does not currently pay a dividend.Dividend GrowthArtemis Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artemis Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.45% of the stock of Artemis Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Miscellaneous chemical products Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ATMS Previous Symbol CUSIPN/A CIKN/A Webwww.artemis-therapeutics.com Phone646-233-1454Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-4.48Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-120,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-520.43%Miscellaneous EmployeesN/A Outstanding Shares5,154,000Market Cap$1.15 million Next Earnings DateN/A OptionableNot Optionable OTC:ATMS Rates by TradingView Receive ATMS News and Ratings via Email Sign-up to receive the latest news and ratings for ATMS and its competitors with MarketBeat's FREE daily newsletter. Artemis Therapeutics (OTCMKTS:ATMS) Frequently Asked Questions How has Artemis Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Artemis Therapeutics' stock was trading at $0.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATMS shares have increased by 124.0% and is now trading at $0.2240. View which stocks have been most impacted by Coronavirus. Has Artemis Therapeutics been receiving favorable news coverage? News stories about ATMS stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Artemis Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Artemis Therapeutics. Who are some of Artemis Therapeutics' key competitors? Some companies that are related to Artemis Therapeutics include Element Solutions (ESI), WD-40 (WDFC), Cabot (CBT), Orion Engineered Carbons (OEC), Pure Bioscience (PURE), Advanced Emissions Solutions (ADES), Flotek Industries (FTK), HighCom Global Security (HCGS), Ener-Core (ENCR) and GlyEco (GLYE). View all competitors. Who are Artemis Therapeutics' key executives? Artemis Therapeutics' management team includes the following people: Mr. Chanan Morris, Chief Financial Officer (Age 53)Prof. Dana Wolf, Chief Scientific Officer (Age 62)Mr. Brian M. Culley, Chief Exec. Officer (Age 48) What is Artemis Therapeutics' stock symbol? Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS." How do I buy shares of Artemis Therapeutics? Shares of ATMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Artemis Therapeutics' stock price today? One share of ATMS stock can currently be purchased for approximately $0.22. How big of a company is Artemis Therapeutics? Artemis Therapeutics has a market capitalization of $1.15 million. What is Artemis Therapeutics' official website? The official website for Artemis Therapeutics is www.artemis-therapeutics.com. How can I contact Artemis Therapeutics? Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The company can be reached via phone at 646-233-1454 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
